BIOTRIN PARVOVIRUS IGM EIA (V619IMUS)

Assay,enzyme Linked Immunosorbent,parvovirus B19 Igm

FDA Premarket Approval P970055

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

The device is intended for the qualitative detection if igm antibodies to b19 virus (b19v, previously known as human parvovirus b19) in human seru, lithium heparin, edta, and citrated plasma. This test, in conjunction with the biotrin parvovirus b19 igg enzyme immunoassay, may be used for testing women of childbearing age to determine their serological status where there is a suspicion of exposure with b19v. The results of these assays may be used to make a serological determination of past, recent, or current infection with b19v. The clinician should consider the results of these assays as presumptive for risk of fetal infection with b19v. The test may also be used for all patients as an aid in the diagnosis of fifth disease (erythema infectiosum).

DeviceBIOTRIN PARVOVIRUS IGM EIA (V619IMUS)
Classification NameAssay,enzyme Linked Immunosorbent,parvovirus B19 Igm
Generic NameAssay,enzyme Linked Immunosorbent,parvovirus B19 Igm
ApplicantDIASORIN
Date Received1997-08-28
Decision Date1999-08-06
PMAP970055
SupplementS
Product CodeMYM
Docket Number00M-1215
Advisory CommitteeMicrobiology
Expedited ReviewNo
Combination Product No
Applicant Address DIASORIN 1951 Northwestern Avenue stillwater, MN 55082-0285
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P970055Original Filing
S022 2021-11-23 30-day Notice
S021 2020-07-16 30-day Notice
S020 2020-03-30 30-day Notice
S019 2019-03-22 30-day Notice
S018
S017 2018-08-08 Normal 180 Day Track No User Fee
S016
S015 2017-02-08 30-day Notice
S014 2016-12-22 30-day Notice
S013 2013-11-27 30-day Notice
S012 2011-12-06 30-day Notice
S011 2011-07-06 30-day Notice
S010 2011-06-24 Normal 180 Day Track No User Fee
S009 2010-05-14 30-day Notice
S008 2010-02-17 30-day Notice
S007 2009-02-09 30-day Notice
S006 2007-07-31 30-day Notice
S005 2007-06-01 135 Review Track For 30-day Notice
S004 2007-05-14 30-day Notice
S003
S002 2005-03-23 30-day Notice
S001 2002-11-15 Special (immediate Track)

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.